Updated:
Venus Medtech
Venus Medtech launched in 2009 in Hangzhou, founded by Eric Zi and Frank Zeng to develop transcatheter aortic valve replacement (TAVR) devices for China's...
Venus Medtech
Venus Medtech launched in 2009 in Hangzhou, founded by Eric Zi and Frank Zeng to develop transcatheter aortic valve replacement (TAVR) devices for China's rapidly aging population. The company listed on the Hong Kong Stock Exchange in 2019, raising roughly $330 million in what was then the largest medical device IPO in the city's history (per Reuters, 2019). Its original wealth creation stems from the commercialization of VenusA-Valve, the first TAVR device approved by China's National Medical Products Administration. As a corporate investor, Venus Medtech deploys capital through direct R&D and the Ascendum Capital Partners platform, a joint vehicle with Qiming Venture Partners and DCP Capital targeting early-stage cardiovascular technologies. The firm's primary focus is transcatheter heart valve systems — aortic, pulmonary, mitral, and tricuspid — alongside ancillary devices for structural heart interventions. Confirmed portfolio investments include the VenusP-Valve system for congenital heart disease and next-generation retrievable TAVR devices. Geographically, the firm operates from Hangzhou and Hong Kong, with clinical trial footprints across China, Europe, and select emerging markets. In 2025, the firm's governance was upended when co-founders Eric Zi and Frank Zeng were dismissed following an internal investigation into unauthorized loans made without board approval (per public filings, 2025). The firm maintains a physical presence through its Hangzhou headquarters, a Hong Kong operations center, and the Qiming Healthcare Life Science Industrial Park in the Hangzhou National High-Tech Industrial Development Zone. The co-founders' controlling stake was held through Red Giant Limited. Venus Medtech's structural differentiator is its hybrid posture as a publicly traded medical device manufacturer that also operates a dedicated investment platform for pipeline acquisitions. Unlike a typical corporate VC arm, Ascendum Capital Partners formalized co-investment rights for external backers Qiming and DCP, creating a syndicated model for cardiovascular deal-making that sits alongside the company's internal R&D engine. The 2025 governance crisis raises unresolved questions about succession and who controls investment decisions going forward.
General information
Firm type
Corporate Investor
Year founded
2009
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Hangzhou
Corporate office
Room 311, 3/F, Block 2, No. 88, Jiangling Road, Binjiang District, Hangzhou, Zhejiang, China
Additional offices
Wanchai, Hong Kong
Principals
Zi Zhenjun (Eric Zi)
Co-founder and former CEO
Zeng Min (Frank Zeng)
Co-founder and former Chairman
Sector focus
Frequently asked questions
Who runs investment decisions at Venus Medtech following the 2025 founder dismissals?
As of mid-2025, the board has not publicly named permanent replacements for ousted co-founders Eric Zi and Frank Zeng. The company's Hong Kong Stock Exchange filings confirm an interim management structure, but investment committee composition for the Ascendum Capital Partners platform has not been disclosed. Given the governance overhaul, external co-investors Qiming Venture Partners and DCP Capital may hold enhanced influence over pipeline decisions.
How is Venus Medtech related to Ascendum Capital Partners?
Ascendum Capital Partners is a co-investment platform Venus Medtech established alongside Qiming Venture Partners and DCP Capital to fund early-stage cardiovascular device companies. It operates as a dedicated investment vehicle rather than a standard corporate venture arm, giving external partners direct co-investment rights alongside Venus Medtech's own balance sheet capital.
What is Venus Medtech's known posture on acquisitions versus organic R&D?
Venus Medtech historically pursued a dual-track strategy: internal development of its core TAVR franchise (VenusA-Valve and VenusP-Valve) and acquisition of complementary technologies through the Ascendum Capital Partners platform. The firm's Hong Kong IPO prospectus emphasized in-licensing and M&A as key growth levers, particularly for mitral and tricuspid valve programs.
Does Venus Medtech invest outside of cardiovascular devices?
No. The firm's entire investment thesis centers on structural heart disease, spanning transcatheter aortic, pulmonary, mitral, and tricuspid valve technologies. Public filings and its Ascendum Capital Partners mandate show no diversification into other medical device categories or therapeutic areas.
What happened to the co-founders' stake following the 2025 dismissals?
Eric Zi and Frank Zeng's holdings remain held through Red Giant Limited, a Hong Kong-registered entity that controls a significant share block. The 2025 dismissals removed their executive authority but did not automatically trigger a forced share sale. The ongoing legal and regulatory review may affect their voting rights and eventual disposition of the stake.
How does Venus Medtech's investment model differ from a typical corporate venture capital arm?
Unlike a traditional CVC that allocates a fixed percentage of balance sheet cash, Venus Medtech structured Ascendum Capital Partners as a formal co-investment platform with external institutional partners Qiming and DCP. This syndicated model mirrors private equity deal structures more than standard corporate venturing, giving external partners governance rights over investment decisions.
Is Venus Medtech still actively deploying capital given the 2025 governance crisis?
The firm has not publicly updated its investment cadence since the founder dismissals. Hong Kong Stock Exchange filings indicate ongoing clinical trial activity and product commercialization, but no new Ascendum Capital Partners deals have been announced post-governance change. Allocators should assume a paused or reduced investment pace until permanent leadership is confirmed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: